PHILADELPHIA (January 3, 2024) — The Pancreatic Cancer Cure Foundation (PCCF) has donated $30,000 to help fund ongoing research at the Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center.
PHILADELPHIA (December 21, 2023) —On November 8, 2023, the entire team at Fox Chase Cancer Center’s Huntingdon Pike ambulatory care clinic celebrated 365 days of successfully preventing patient falls. While falls were never common at HP, the nursing staff developed a home-grown recipe for fall prevention that included both new procedures and an overall dedication to finding and eliminating potential hazards. As a result, they have gone fall-free for an entire year.
PHILADELPHIA (December 20, 2023) — Rebecca Shulman, MD, an Assistant Professor in the Department of Radiation Oncology at Fox Chase Cancer Center, was recently recognized with the American Society for Radiation Oncology (ASTRO)-Breast Cancer Research Foundation (BCRF) Emerging Investigator Award to Build a Diverse Scientific Workforce.
Fox Chase Cancer Center partnered with the Damon Runyon Cancer Research Foundation to present a panel presentation, “A Serious Conversation About Cancer,” which focused on some of the latest developments in cancer research and treatment by top oncology leaders.
PHILADELPHIA (December 14, 2023) — Zoe Landau, MPH, Project Manager in the lab of Linda Fleisher, PhD, MPH, a Research Professor in the Cancer Prevention and Control Research Program at Fox Chase Cancer Center, was recently recognized with the Best Professional Poster Award at the 2023 International Cancer Education Conference (ICEC) for her work detailing the mychoice digital health tool.
PHILADELPHIA (December 11, 2023) — Fox Chase Cancer Center graduate student Billy Truong was awarded the American Society of Hematology (ASH) Abstract Achievement Award for the third year in a row for his study on targeting substrate interactions of the ERK2 protein that drive myeloproliferative neoplasms (MPN).
PHILADELPHIA (December 11, 2023) — Asya Varshavsky-Yanovsky, MD, PhD, an Assistant Professor in the Department of Bone Marrow Transplant and Cellular Therapies at Fox Chase Cancer Center, has presented an analysis showing that the multiple myeloma drug elranatamab is safe and effective for Black or African American patients with relapsed/refractory multiple myeloma (RRMM).